ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Debashis Sarker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.